Stock of The Day: Apricus Biosciences Inc’s Stock Is Sell After Touching All-Time Low

Stock of The Day: Apricus Biosciences Inc's Stock Is Sell After Touching All Time Low

The stock of Apricus Biosciences Inc (NASDAQ:APRI) reached all time low today, Oct, 31 and still has $1.84 target or 14.00% below today’s $2.14 share price. This indicates more downside for the $15.73 million company. This technical setup was reported by Barchart.com. If the $1.84 PT is reached, the company will be worth $2.20 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 22,100 shares traded hands. Apricus Biosciences Inc (NASDAQ:APRI) has declined 63.71% since March 29, 2016 and is downtrending. It has underperformed by 67.18% the S&P500.

Analysts await Apricus Biosciences Inc (NASDAQ:APRI) to report earnings on November, 3. They expect $-0.07 earnings per share, up 30.00% or $0.03 from last year’s $-0.1 per share. After $-0.08 actual earnings per share reported by Apricus Biosciences Inc for the previous quarter, Wall Street now forecasts -12.50% EPS growth.

Apricus Biosciences Inc (NASDAQ:APRI) Ratings Coverage

Out of 5 analysts covering Apricus Bioscience Inc (NASDAQ:APRI), 2 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 40% are positive. Apricus Bioscience Inc has been the topic of 6 analyst reports since August 6, 2015 according to StockzIntelligence Inc. FBR Capital maintained Apricus Biosciences Inc (NASDAQ:APRI) on Friday, November 6 with “Outperform” rating. The stock of Apricus Biosciences Inc (NASDAQ:APRI) earned “Neutral” rating by Sterne Agee CRT on Wednesday, December 9. Ascendiant Capital Markets initiated the shares of APRI in a report on Thursday, August 13 with “Buy” rating. The firm has “Neutral” rating by TH Capital given on Friday, November 6. The firm has “Neutral” rating given on Friday, November 6 by Roth Capital.

According to Zacks Investment Research, “Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT ®. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California.”

More news for Apricus Biosciences Inc (NASDAQ:APRI) were recently published by: Seekingalpha.com, which released: “Reverse Stock Split: Apricus Bio” on October 31, 2016. Globenewswire.com‘s article titled: “Apricus Biosciences Announces Approval of Vitaros® for the Treatment of …” and published on October 26, 2016 is yet another important article.

APRI Company Profile

Apricus Biosciences, Inc., incorporated on October 20, 1987, is a pharmaceutical company, which develops pharmaceutical products. The Firm primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. It has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Firm has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment